This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
ShedRx para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
Now branded as Shed, this all-50-state cash-pay program offers compounded injections and oral formulations plus FDA-approved brands, with flat dose pricing, coaching, care-team access, and free shipping. Public prices begin at $159 for compounded semaglutide and $239 for compounded tirzepatide.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)
- Formats reviewed
- Injection · Oral medicine
- Funding routes
- Private pay
- Service features
- Clinician support · Switching pathway · Home delivery
- Access check
- Provider coverage published; confirm treatment
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 4 medicine rows · 4 open checks
Recurring cost breakdown
- Compounded semaglutide from $159/month.
- Compounded tirzepatide from $239/month.
- Health coaching, care-team access, nutrition/exercise resources, and standard shipping are included in GLP-1 plans.
- No insurance is required; HSA/FSA may be used for eligible services.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Compounded semaglutide | Weekly injection | Not FDA-approved | From $159/month |
| Compounded tirzepatide | Weekly injection | Not FDA-approved | From $239/month |
| GLP-1 liquid drops / lozenges | Daily oral liquid / sublingual | Compounded; exact ingredient requires confirmation | Verify product page |
| Foundayo / Wegovy / Zepbound | Pill or weekly injection | FDA-approved brands | Verify live route |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- Shed states that telehealth services are available in all 50 states.
- Treatment availability can still vary with medical and regulatory requirements.
Clinician access and follow-up cadence
- A licensed provider reviews the online assessment; a live meeting depends on state and treatment.
- Members can contact a medical provider, nursing team, health coach, and support team through the portal.
- Coaching meetings are available as needed rather than on one mandatory published schedule.
Pharmacy and fulfillment
- Prescription treatment ships to the patient with free standard shipping.
- Compounded medication is prepared by a licensed pharmacy, but a state-by-state named-pharmacy assignment is not published on the main page.
Insurance and prior authorization
- The program is designed for cash pay without insurance.
- HSA/FSA use depends on eligibility and plan rules.
Cancellation, refund, and commitment
- The main program page does not summarize cancellation timing; the detailed terms govern renewal and processed orders.
- The 120-day weight-loss guarantee has eligibility and adherence conditions and should not be treated as an unconditional refund.
Labs, monitoring, and dose management
- No universal included lab panel was confirmed on the main page.
- Provider review and ongoing support are included; medication-specific testing is individualized.
Maintenance and switching
- Flat-dose pricing reduces one source of escalation if the clinician changes dose.
- Existing-dose continuation and oral/injectable substitutions require new clinical review.
Program snapshot
Treatment-specific cash program
Profiled support: Ongoing clinician access.
Cash pay
The reviewed weight-loss path is positioned as cash pay.
Verify before purchase
Request the dispensing pharmacy and exact formulation before paying.
What the advertised program may include
- Telehealth intake
- Clinician review
- Medication when prescribed
- Follow-up according to plan
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- Named pharmacy by state
- Universal lab protocol
- Simplified public cancellation cutoff
- Price for every oral and brand route
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Current products, prices, all-state access, flat-dose pricing, support and shipping
Subscription, cancellation and guarantee terms